Cell Bio Human Tech Co.,Ltd (KOSDAQ:318160)
South Korea · Delayed Price · Currency is KRW 6,370.00
+460.00 (7.78%)
At close: Aug 24, 2026
KOSDAQ:318160 Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 53,354 | 66,620 | 27,645 | 37,862 | - | - | |
Market Cap Growth | -29.63% | 140.98% | -26.98% | - | - | - |
Enterprise Value | 57,995 | 62,798 | 17,671 | 33,014 | - | - |
Last Close Price | 6370.00 | 8170.00 | 3150.00 | 4090.00 | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 5.76 | 7.64 | 6.31 | - | - | - |
PS Ratio | 0.96 | 1.31 | 0.97 | 1.39 | - | - |
PB Ratio | 0.87 | 1.13 | 0.60 | 0.85 | - | - |
P/TBV Ratio | 0.94 | 1.22 | 0.62 | 0.88 | - | - |
P/FCF Ratio | - | - | 3.82 | 33.46 | - | - |
P/OCF Ratio | 17.51 | 44.81 | 2.98 | 21.52 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.04 | 1.23 | 0.62 | 1.21 | - | - |
EV/EBITDA Ratio | 4.81 | 5.34 | 2.97 | 6.67 | - | - |
EV/EBIT Ratio | 6.23 | 6.74 | 4.38 | 10.48 | - | - |
EV/FCF Ratio | - | - | 2.44 | 29.18 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.34 | 0.35 | 0.09 | 0.13 | 0.14 | 0.38 |
Debt / EBITDA Ratio | 1.75 | 1.75 | 0.68 | 1.20 | 0.97 | 2.05 |
Debt / FCF Ratio | - | - | 0.56 | 5.24 | 67.51 | 3.77 |
Net Debt / Equity Ratio | 0.03 | 0.07 | -0.22 | -0.17 | -0.04 | -0.17 |
Net Debt / EBITDA Ratio | 0.17 | 0.33 | -1.72 | -1.53 | -0.31 | -0.94 |
Net Debt / FCF Ratio | -0.70 | -0.76 | -1.41 | -6.68 | -21.46 | -1.73 |
Asset Turnover | 0.76 | 0.72 | 0.54 | 0.55 | 0.53 | 0.66 |
Inventory Turnover | 3.39 | 3.50 | 3.02 | 2.25 | 2.59 | 4.69 |
Quick Ratio | 1.56 | 1.43 | 2.92 | 2.08 | 1.29 | 2.61 |
Current Ratio | 2.43 | 2.29 | 3.82 | 3.15 | 2.57 | 3.34 |
Return on Equity (ROE) | 16.84% | 16.50% | 9.63% | -4.49% | 7.52% | 7.51% |
Return on Assets (ROA) | 7.97% | 8.24% | 4.76% | 3.97% | 4.25% | 6.62% |
Return on Invested Capital (ROIC) | 14.15% | 18.20% | 9.31% | 8.58% | 8.43% | 12.13% |
Return on Capital Employed (ROCE) | 13.00% | 13.50% | 8.70% | 7.10% | 9.20% | 11.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 17.34% | 13.09% | 15.84% | -4.91% | - | - |
FCF Yield | -5.43% | -7.73% | 26.21% | 2.99% | - | - |
Buyback Yield / Dilution | 4.58% | 8.00% | -5.59% | -20.68% | 11.32% | 1.95% |